Benjamin A Weinberg, ASCO GI22: Pivotal Studies in Colorectal Cancer

Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) summarises key data from pivotal studies in colorectal cancer that were presented at the ASCO Gastrointestinal Cancers Symposium 2022.

• GALAXY study in CIRCULATE-Japan abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.009 

Clinical trial information: jRCT1031200006

• RESPECT study abstract: https://meetings.asco.org/abstracts-presentations/204531

Clinical Trial Registration Number: UMIN000008866

• GERCOR NIPICOL study abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.013

Clinical trial information: NCT033501260.

Questions

1.          What has the GALAXY study taught us about ctDNA dynamics and clinical outcomes in the management of patients with resectable colorectal cancer (CRC)? (00:15-01:45)
2.           Following the RESPECT study, what should be the preferred first-line treatment for patients with metastatic (m)CRC aged 75+? (01:45-03:30)
3.           According to the latest GERCOR NIPICOL data, when is the best time to stop immunotherapy in patients with microsatellite instability-high/mismatch repair deficient mCRC? (03:30-05:01)
4.           What have we learned about the use of neoadjuvant dostarlimab for MSI-H locally advanced CRC? (05:01-06:10)
5.           What is the potential of BEACON plus nivolumab for BRAF V600E mutated mCRC? (06:10-07:52)

Speaker Disclosure: Benjamin A Weinberg has no conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ASCO Gastrointestinal Cancers Symposium 2022.